You are here: Industry Insights > ICML

News List

Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML) PharmaSources
June 16, 2023
On June 16, 2023,InnoCare Pharma, a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 21, 2021
InnoCare announced the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on MPresents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma prnasia
June 18, 2021
InnoCare announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML).